Telomir Pharmaceuticals, Inc. (TELO): R&D Expense
$2.44M
Year ended 2025-12-31
$2.97M
Trailing 12 months to 2026-06-30
+43.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.44M | +9.0% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $2.24M | +42.0% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $1.57M | +88.9% | 2025-02-04, From 2023-01-01 |
| 2022-12-31 | $833.2K | n/a | 2024-03-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $2.44M | +9.0% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $85.0K | -99.3% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $13.31M | -13.8% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $5.95M | +83.0% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $1.83M | -66.1% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
Compare TELO, ENSC, MTNB, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗